مورد إلكتروني
Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.
| العنوان: | Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study. |
|---|---|
| المؤلفون: | Johnson N.A., Lavie D., Borchmann P., Gregory G., Herrera A.F., Minuk L., Vucinic V., Armand P., Avigdor A., Gasiorowski R., Herishanu Y., Keane C., Kuruvilla J., Palcza J., Pillai P., Marinello P., Timmerman J. |
| بيانات النشر: | American Society of Clinical Oncology Netherlands 2022-09-02 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Background: PD-1 inhibitors are a standard of care in pts with R/R cHL but new approaches are still needed to deepen and lengthen responses. Dual blockade of PD-1 and LAG-3 has demonstrated antitumor activity in preclinical models. The multicohort phase 1/2 MK-4280-003 study (NCT03598608) evaluated the safety and efficacy of favezelimab (MK-4280), a humanized IgG4 LAG-3 inhibitor, plus pembrolizumab (pembro; a PD-1 inhibitor) in pts with R/R hematologic malignancies. This analysis focused on anti-PD-1-naive pts with R/R cHL (cohort 1). Method(s): This study included a safety lead-in phase (part 1) to determine the recommended phase 2 dose (RP2D) followed by a dose-expansion phase (part 2). Eligible pts in cohort 1 must have R/R cHL after autologous stem cell transplantation (ASCT) or be ineligible for ASCT and have had no prior anti-PD-1 therapy. In part 1, patients from all cohorts received pembro IV 200 mg Q3W and favezelimab IV 200 mg or 800 mg Q3W. Dose escalation followed the mTPI design. In part 2, pts received pembro + favezelimab at the established RP2D for up to 35 cycles. Primary end point was safety. Secondary end point was ORR. DOR, PFS, and OS were exploratory end points. Result(s): Only 1 dose-limiting toxicity (DLT; autoimmune hepatitis [grade 4]) was identified among the first 6 pts from all cohorts in part 1 at the favezelimab 200 mg dose; thus, the dose was escalated to 800 mg. No DLTs were observed in the 15 additional pts treated at the 800 mg dose. The RP2D for the combination was defined as 800 mg Q3W + pembro 200 mg Q3W. In cohort 1, 30 pts were enrolled; median age was 40 years, 53% had ECOG PS 0, and 80% had <=3 prior lines of therapy. After a median follow-up of 13.5 mo, ORR for cohort 1 was 73% (95% CI, 54-88; CR, 7 pts [23%]; PR, 15 pts [50%]). 28 of 30 pts (93%) had reduction from baseline in target lesions. Median DOR was not reached (NR; 95% CI, 0+ to 23+ mo); 6 pts (51%) had response >=12 mo. Median PFS was 19 mo (95% CI, 8-NR); 12-mo |
| مصطلحات الفهرس: | Conference Abstract |
| URL: | Journal of Clinical Oncology |
| الإتاحة: | Open access content. Open access content |
| أرقام أخرى: | AUSHL oai:repository.monashhealth.org:1/48688 Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 2022. Online. 40(16 Supplement 1) (no pagination), 2022. Date of Publication: June 2022. https://repository.monashhealth.org/monashhealthjspui/handle/1/48688 (Johnson, Lavie, Borchmann, Gregory, Herrera, Minuk, Vucinic, Armand, Avigdor, Gasiorowski, Herishanu, Keane, Kuruvilla, Palcza, Pillai, Marinello, Timmerman) 1Jewish General Hospital, Montreal, QC, Canada; Hadassah Medical Center, Jerusalem, Israel; University Hospital of Cologne, Cologne, Germany; School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia; City of Hope, Duarte, CA; CancerCare Manitoba, Winnipeg, MB, Canada; University of Leipzig Medical Center, Leipzig, Germany; Dana-Farber Cancer Institute, Boston, MA; Sheba Medical Center, Ramat Gan, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Concord Hospital, University of Sydney, Concord, NSW, Australia; Tel Aviv Sourasky Medical Center, Tel Aviv-Yafo, Israel; Princess Alexandra Hospital, Brisbane, QLD, Australia; Princess Margaret Cancer Centre, Toronto, ON, Canada; Merck and Co., Inc., Kenilworth, NJ; UCLA Medical Center, Los Angeles, CA 1346233546 |
| المصدر المساهم: | MONASH HEALTH LIBRS From OAIster®, provided by the OCLC Cooperative. |
| رقم الأكسشن: | edsoai.on1346233546 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |